217 related articles for article (PubMed ID: 26250968)
1. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
2. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.
Jones NL; Xiu J; Reddy SK; Burke WM; Tergas AI; Wright JD; Hou JY
Gynecol Oncol; 2015 Sep; 138(3):620-6. PubMed ID: 26123645
[TBL] [Abstract][Full Text] [Related]
3. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
5. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
12. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
Liang SX; Chambers SK; Cheng L; Zhang S; Zhou Y; Zheng W
Int J Surg Pathol; 2004 Oct; 12(4):319-31. PubMed ID: 15494858
[TBL] [Abstract][Full Text] [Related]
13. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
16. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Klc TR; Wu S; Wilhite AM; Jones NL; Powell MA; Olawaiye A; Girda E; Brown J; Puechl A; Ali-Fehmi R; Winer IS; Herzog TJ; Korn WM; Erickson BK
Gynecol Oncol; 2022 Nov; 167(2):289-294. PubMed ID: 36114027
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of 14-3-3σ is predictive of poor prognosis for patients with human uterine papillary serous carcinoma.
Suzuki F; Nagase S; Suzuki K; Oba E; Hiroki E; Matsuda Y; Akahira J; Nishigori H; Sugiyama T; Otsuki T; Yoshinaga K; Takano T; Niikura H; Ito K; Sasano H; Yaegashi N
Tohoku J Exp Med; 2013 Nov; 231(3):193-9. PubMed ID: 24201220
[TBL] [Abstract][Full Text] [Related]
18. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
[TBL] [Abstract][Full Text] [Related]
19. Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.
Lopez S; Cocco E; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Terranova C; Angioli R; Santin AD
Mol Cancer Ther; 2015 Nov; 14(11):2519-26. PubMed ID: 26333383
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
